Stereotactic Body Radiation Therapy Versus Radiofrequency Ablation for Small Renal Masses (SBRT vs RFA)
A Prospective Randomized Pilot Trial of Stereotactive Body Radiation Therapy Versus Radiofrequency Ablation for the Management of Small Renal Masses.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ontario
-
Hamilton, Ontario, Canada, L8N 4A6
- McMaster Institute of Urology - St. Joseph's Healthcare Hamilton
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients ≥18 years of age and capable of providing informed consent
- Patients scheduled for treatment of their SRM using SBRT or RFA
- Patients who received a biopsy of their SRM prior to their scheduled SBRT or RFA treatment
- Patients who are willing to have a biopsy 12 months post-procedure
- Patients with renal tumor(s) ≤ 4.0 cm
Exclusion Criteria:
- Patients with large renal tumor(s)>4.0 cm
- Patients who are unable to have a general anesthetic
- Patients who did not receive a biopsy of their SRM prior to their scheduled SBRT or RFA treatment
- Patients who are unable to comply with post-operative and/or follow-up protocol/phase of study
- Evidence of metastatic disease
- Uncorrectable bleeding diathesis
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: SINGLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: Stereotactic body radiation therapy (SBRT)
|
The Gross Tumour Volume (GTV) is defined as the visible tumour seen on the planning CT simulation.
No clinical target volume (CTV) for microscopic disease is necessary.
The internal target volume (ITV) accounts for changes in tumour position due to respiration, and is assessed on 4DCT.
The planning target volume (PTV) will be a standard 0.5 cm around the ITV.
Other Names:
|
|
ACTIVE_COMPARATOR: Radiofrequency Ablation (RFA)
|
RFA probe will create an ablation zone of a 1.0 cm diameter beyond the maximum CT-measured tumor diameter.
The generator will modulate power up to 150 W in reach average ablative temperature of 105oC.
Tumors will be treated for two cycles of 8 minutes duration each upon reaching target temperatures.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Treatment failure
Time Frame: 12 Months
|
Failure will be defined as enhancement of ablated tissue greater than 10 Hounsfield units by CT contrast.
|
12 Months
|
|
Overall Survival
Time Frame: 12 Months
|
Defined as post-procedural survival.
|
12 Months
|
|
Disease free survival
Time Frame: 12 Months
|
Defined as disease-free survival rate after a single procedure
|
12 Months
|
|
Disease recurrence
Time Frame: 12 Months
|
Defined as disease recurrence rate after a single procedure, including positive biopsy result.
|
12 Months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Tumour Size
Time Frame: 12 Months
|
Average percentage decrease in tumor size.
|
12 Months
|
|
Renal Function -eGFR
Time Frame: 12 Months
|
Change in eGRF measured by mL/min/1.73m2.
|
12 Months
|
|
Renal Function - Serum Creatinine
Time Frame: 12 Months
|
Change in serum creatinine level measured by umol/L.
|
12 Months
|
|
Renal Function - Creatinine Clearance
Time Frame: 12 Months
|
Change in creatinine clearance measured by ml/minute.
|
12 Months
|
|
Complication Rate
Time Frame: 12 Months
|
Intra and post intervention complication rates will be documented in terms of nausea, vomiting, diarrhea, hematuria, hemorrhage (requiring or not requiring transfusion), perinephric hematoma, ureteral strictures, loss of a renal unit, urinary leak, bleeding, fever and flulike symptoms, stomach/bowel ulceration, ureteropelvic junction obstruction, and upper pole hydrocalycosis.
|
12 Months
|
|
Number of patients that experienced an adverse event.
Time Frame: 12 Months
|
Defined by any adverse event listed in the CTCAE.
|
12 Months
|
|
Change in score for quality of life
Time Frame: 12 Months
|
Defined by the generic EuroQol (EQ-5D) questionnaire that is a standardized measure of health.
A scale of 0-100 (0 being the worse health, and 100 being the best health), is used for a patient to define their overall health and wellbeing.
|
12 Months
|
|
Duration of hospital stay
Time Frame: Days
|
Duration of length of hospital stay (if applicable)
|
Days
|
|
Cost analysis
Time Frame: 12 Months
|
Defined by total cost of procedure and any associated related adverse events post procedure.
|
12 Months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Anil Kapoor, MD FRCSC, St. Joseph's Healthcare Hamilton
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ANTICIPATED)
Primary Completion
Study Completion (ANTICIPATED)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- RADSTER
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.